Press release
June 14, 2022
NCI/NIH Award $2 Million to Immunicom to Initiate Clinical Trial Evaluating Breakthrough Immunopheresis® LW-02 Molecular Subtractive Therapy in Refractory ER+/Her2- Breast Cancer
June 2, 2022
Immunicom Clinical Trial Data at ASCO 2022 Show Immunopheresis® LW-02 Column Safe and Effectively Depletes Soluble TNF-α Receptors in Patients with Advanced Triple Negative Breast Cancer
April 28, 2022
Immunicom Presents New Data at AACR 2022 of LW-02 Cartridge Immunopheresis® Therapy from Ongoing mTNBC Clinical Trial in Chemo-Refractory Patients
April 12, 2022
Immunicom Announces Addition of Key Industry Leaders to Board of Directors
March 3, 2022